Ligand acquires milestone and royalty rights to SB206 from Novan

Ligand acquires milestone and royalty rights to SB206 from Novan

Source: 
Pharmaceutical Business Review
snippet: 

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.